Virogenbio Inc.

Virogenbio is a global biotechnology company focused on the development of innovative medicines for immunotherapies addressing unmet needs across a range of therapeutic areas.

Holding worldwide development and commercialization rights, the company leads global clinical development and alliance management from its U.S. operations, with plans to expand its presence to the European Union.

Founders & Team

Su Chen

Su Chen

CEO

Company Founder,MS, MBA ,30+ years experience in the global biopharma industry with deep expertise across CMC, quality, regulatory filing, clinical development, product launch, and entrepreneurial leadership in scaling biotech programs and infrastructure
Patricia Golkowski

Patricia Golkowski

CFO

MBA, CPA ,15+ years of experience leading finance and strategic operations across Fortune 500 companies and high-growth startups
Herbert Hutman

Herbert Hutman

CMO

MD, 20+ years of experience in clinical development, regulatory strategy, and safety surveillance across biotech, pharmaceutical, and medical device sectors
Dan Hoffman

Dan Hoffman

Senior VP (for communication and IR)

25+ years of experience in strategic communications, digital media, and brand development across global broadcast and healthcare platforms

Independent Board members

Simon Choi

Former Executive Director at Morgan Stanley, Lehman Brothers & Goldman Sachs Led $600B+ asset restructuring (2008 GFC) & global risk frameworks at GE Capital Founder & Executive Partner of $10B+ investment platform in US & APAC MBA, Columbia; M.S., Georgia University with global networks & strategic partnerships
Domenick Bertelli

Expertise: Biopharma & MedTech strategy, pricing & reimbursement Global Experience: US & international markets, multiple therapeutic areas Therapeutic Focus: Oncology, immunology, endocrinology, CNS, GI, cardiology, pulmonology, women’s health Previous Roles: McKinsey Engagement Manager; BT Alex. Brown Investment Banking; MIT Lean Aerospace Initiative Education: AB, Harvard University; MBA, MIT Sloan

Independent Board members

Yumeng Zhang, MD

Assistant Member in Lymphoma, Malignant Hematology
Frederick Locke, MD

Vice Chair and Program Co-Leader, Department of Blood and Marrow Transplant and Cellular Immunotherapy
Michael Jain, MD, PhD

Director of Blood, Marrow Transplant & Cellular Immunotherapy
Elizabeth Pomfret, MD, PhD

Chief of Transplant Surgery and Executive Director of the Colorado Center for Transplantation Care, Research and Education
Christene A. Huang, PhD

Professor in Organ Transplant
Usama Gergis, MD

Director, Bone Marrow Transplant & Immune Cellular Therapy

Global Presence

With the only drug capable of resetting the cellular immune system in the world, we are achieving critical breakthroughs for the future cell and immuno therapies

USA

China